THE ARCHIVE
Every forecast,
in order.
38 questions in Biotech. Sorted by newest.
◆ Artificial Intelligence 141▲ Markets & Economy 139⬢ Geopolitics 109▢ Policy & Law 97◇ Gaming 94⚡ Energy 85▽ Security & Defense 76◉ Climate & Environment 69✦ Space 66▣ Consumer Tech 48◈ Crypto & Finance 47❖ Biotech 38✚ Health & Medicine 36▶ Transportation 35
1Y
29 Oct 2027
The FDA approves AbbVie's Biologics License Application for etentamig.
73%
AI
10Y
25 Oct 2036
A clinical trial begins testing a vascularized, 3D-bioprinted human organ in patients before 2032.
22%
AI
10Y
25 Oct 2036
A fully lab-grown solid human organ is successfully transplanted into a patient before 2035.
18%
AI
5Y
27 Oct 2031
Standard clinical turnaround for an ex vivo autologous gene editing therapy falls below 14 days before 2030.
22%
AI
3Y
27 Oct 2029
An in vivo CRISPR gene editing therapy receives standard FDA approval before 2028.
20%
AI
5Y
27 Oct 2031
Human germline gene editing results in a live birth before 2030.
18%
AI
1Y
19 Oct 2027
Cedars-Sinai reports that microgravity improved the production of stem-cell-derived structures from the CRS-35 mission experiments.
38%
AI
50Y
6 Oct 2076
Genetic editing creates a distinct human subspecies before 2050.
3%
AI
50Y
5 Oct 2076
A human life expectancy surpasses 150 years through medical intervention before 2050.
4%
AI
6M
15 Apr 2027
Mount Sinai's CRS-35 tissue model experiment yields publishable data on microgravity-induced aging or functional changes.
60%
AI
10Y
14 Oct 2036
A therapeutic treatment scientifically proven to reverse cellular aging in humans receives regulatory approval before 2035.
12%
AI
1Y
15 Oct 2027
Mount Sinai publishes findings analyzing the returned CRS-35 bioengineered brain and cardiovascular tissue models.
35%
AI
5Y
12 Oct 2031
The first fully functional lab-grown human organ is successfully transplanted into a patient before 2030.
11%
AI
5Y
5 Oct 2031
A fully bioengineered, lab-grown human solid organ is successfully transplanted into a human patient before 2031.
16%
AI
3Y
5 Oct 2029
The FDA suspends or revokes approval of an approved gene-editing therapy due to off-target side effects before 2028.
8%
AI
5Y
5 Oct 2031
The US FDA approves an in vivo CRISPR-based gene editing therapy for common cardiovascular disease before 2030.
16%
AI
5Y
27 Sept 2031
The FDA approves a therapeutic drug with an explicit indication to slow or reverse human biological aging before 2031.
5%
AI
10Y
24 Sept 2036
A fully lab-grown solid human organ is successfully transplanted into a human patient before 2032.
22%
AI
3Y
26 Sept 2029
A gene therapy targeting herpes simplex virus enters Phase 3 clinical trials before 2029.
9%
AI
5Y
26 Sept 2031
The FDA approves at least 10 novel gene therapies in a single calendar year before 2030.
22%
AI
10Y
24 Sept 2036
A clinical trial begins treating human embryos with heritable germline gene editing before 2035.
13%
AI
5Y
26 Sept 2031
An in vivo CRISPR gene-editing therapy receives broad regulatory approval for a common non-rare disease before 2030.
17%
AI
3Y
26 Sept 2029
LambdaVision begins clinical trials for its microgravity-assembled retinal implant by December 31, 2028.
22%
AI
10Y
23 Sept 2036
An AI-designed drug candidate cures or reverses Alzheimer's pathology in human clinical trials before 2036.
9%
AI
6M
21 Mar 2027
Britain's MHRA publishes a regulatory roadmap for space-manufactured pharmaceuticals before the end of 2026.
62%
AI
10Y
17 Sept 2036
The US FDA approves an anti-aging therapeutic indicated specifically to slow biological aging before 2035.
10%
AI
10Y
17 Sept 2036
A fully lab-grown solid organ is successfully transplanted into a human patient in a clinical trial before 2032.
18%
AI
5Y
19 Sept 2031
The US FDA approves a gene therapy targeting sensorineural hearing loss before 2030.
53%
AI
3Y
18 Sept 2029
A gene editing therapy for herpes simplex virus enters Phase 3 clinical trials before 2029.
15%
AI
3Y
18 Sept 2029
The US FDA approves an in vivo CRISPR gene editing therapy before January 1, 2028.
30%
AI
1M
16 Oct 2026
GSK initiates a Phase III efficacy trial for FLUm3HA.b-3NA by September 30, 2026.
65%
AI
1M
14 Oct 2026
GSK starts a Phase III efficacy trial of FLUm3HA.b-3NA in September 2026.✓ happened
44%
AI
1Y
14 Sept 2027
Hualan Biological Vaccine initiates clinical trials for its novel influenza mRNA vaccine.
84%
AI
1M
14 Oct 2026
GSK begins its Phase III efficacy trial for FLUm3HA.b-3NA in September 2026.
63%
AI
1Y
14 Sept 2027
Novo Nordisk resumes clinical development of ziltivekimab.
34%
AI
1Y
14 Sept 2027
The FDA lifts the clinical hold on new patient enrollment in Biohaven's epilepsy drug trials.
67%
AI
1M
14 Oct 2026
The FDA approves zilganersen by its September 22, 2026 PDUFA target action date.✓ happened
77%
AI
1W
21 Sept 2026
The FDA approves zidesamtinib by its September 18, 2026 PDUFA target action date.✓ happened
80%
AI